SEC Tracker
Get the app
NKTR · XBRL financial data

Nektar Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (NKTR's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025†Jun 30, 2025Sep 30, 2025Dec 31, 2025†Apr 23, 2026Jun 30, 2026
Revenue from contracts with customers2424*22232429*10111222*—10
Cost of goods and services sold127*91048*0000*——
Research and development2430*27303529*30302730*—39
General and administrative2117*20211917*24171611*—13
Operating income (loss)(45)(34)*(35)(50)(34)14*(45)(36)(32)(28)*—(42)
Interest income55*4433*3233*—9
Other income (expense)5(21)*(0)(0)(0)(0)*00(0)(0)*—(0)
Income tax expense (benefit)(0)(0)*(0)00(0)*0(0)(0)0*—0
Net income (loss)(46)(42)*(37)(52)(37)7*(51)(42)(36)(36)*—(41)
Earnings per share, basic‡ USD per share(734.69)(673.47)*(581.63)(765.30)(551.02)91.84*(734.69)(42.14)(26.71)——(1.23)
Earnings per share, diluted‡ USD per share(734.69)(673.47)*(581.63)(765.30)(551.02)91.84*(734.69)(42.14)(26.71)——(1.23)
Weighted average shares, basic‡ millions of shares00*0000*011——33
Weighted average shares, diluted‡ millions of shares00*0000*011——33
  • ‡ Per-share figures and share counts are adjusted for the 1-for-14.285714285714285 stock split (March 2025); filings made before it reported them unadjusted.
  • ‡ Per-share figures and share counts are adjusted for the 1-for-14.999925000374997 stock split (December 2024); filings made before it reported them unadjusted.
  • ‡ Per-share figures and share counts are adjusted for the 1-for-14.285714285714285 stock split (March 2026); filings made before it reported them unadjusted.
  • † Share count changed about 22x in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 17x in the period ending 2026-04-23, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (NKTR's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025†Jun 30, 2025Sep 30, 2025Dec 31, 2025†Apr 23, 2026Jun 30, 2026
Cash and cash equivalents65354928304439434115—39
Marketable securities308268241243214211180133229231—645
Marketable securities, non-current—2637195142000—339
Accounts receivable214100——————
Inventory1516161400———0——
Total current assets399331320295286261230187281266—739
Property and equipment, net20191715433332——
Right-of-use asset1918179988873——
Goodwill00——————————
Total assets442398396343308304256208301280—1,095
Accounts payable3109691218141611—25
Accrued liabilities30222430323031352922—23
Total current liabilities52515257686171716654—71
Lease liability, non-current102999591878378747065—56
Total liabilities283267269264259243243232216191—192
Accumulated deficit(3,435)(3,477)(3,514)(3,566)(3,603)(3,596)(3,647)(3,689)(3,724)(3,760)—(3,846)
Total stockholders' equity15913112780496114(24)8590—903
Total liabilities and equity442398396343308304256208301280—1,095
Common shares outstanding (cover page)‡ millions of shares00000001123434
  • ‡ Per-share figures and share counts are adjusted for the 1-for-14.285714285714285 stock split (March 2025); filings made before it reported them unadjusted.
  • ‡ Per-share figures and share counts are adjusted for the 1-for-14.999925000374997 stock split (December 2024); filings made before it reported them unadjusted.
  • ‡ Per-share figures and share counts are adjusted for the 1-for-14.285714285714285 stock split (March 2026); filings made before it reported them unadjusted.
  • † Share count changed about 22x in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 17x in the period ending 2026-04-23, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (NKTR's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025†Jun 30, 2025Sep 30, 2025Dec 31, 2025†Apr 23, 2026Jun 30, 2026
Net income (loss)(46)(42)*(37)(52)(37)7*(51)(42)(36)(36)*—(41)
Depreciation and amortization—year only———year only——————
Net cash from operating activities(42)*(47)*(48)(38)*(44)*(46)*(49)(46)*(49)*(65)*—(76)*
Purchases of property and equipment0*0*00*1*0*00*0*0*—0*
Net cash from investing activities56*17*1917*46*60*4450*(95)*0*—(399)*
Share repurchases0*0*30*0*0*00*0*0*——
Net cash from financing activities0*0*420*0*0*00*142*39*—365*
Net change in cash14*(30)*13(21)*2*14*(5)4*(2)*(26)*—(110)*
  • † Share count changed about 22x in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 17x in the period ending 2026-04-23, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Nektar Therapeutics3910(76)*34.1M9.0 quarters 10-QJun 30, 2026
Aura Biosciences68not reported(33)*103.7M2.1 quarters 10-QJun 30, 2026
Prothena Corp Public2881(25)*51.3M11.5 quarters 10-QJun 30, 2026
Altimmune63not reported(24)*194.5M13.5 quarters 10-QJun 30, 2026
Usana Health Sciences16922323*18.5M— 10-QJul 4, 2026
Rigel Pharmaceuticals617931*18.7M— 10-QJun 30, 2026
Siga Technologies1184115*71.8M— 10-QJun 30, 2026
Amarin157409.2*not reported— 10-QSep 30, 2026
Northwest Biotherapeutics0.60.8(7.2)*1.7B0.1 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.